Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45555 | 0.78 | KDM4E (0.35) | NOS1KMT2A | |
| SCHEMBL1421802 | 0.74 | NOS1 (0.35) | NOS1 | |
| SCHEMBL9996915 | 0.74 | GAA (0.41) | NOS1KMT2A | |
| SCHEMBL3205489 | 0.74 | NOS1 (0.35) | NOS1DYRK1A | |
| SCHEMBL271615 | 0.74 | — | — | |
| SCHEMBL5252596 | 0.74 | — | — | |
| SCHEMBL18687434 | 0.71 | TRPA1 (0.31) | — | |
| SCHEMBL31224907 | 0.69 | — | — | |
| SCHEMBL17326272 | 0.69 | TRPA1 (0.33) | DYRK1A | |
| SCHEMBL4543667 | 0.69 | METAP2 (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-111465603-B | Triazolopyridines as gamma secretase modulators | 勃林格殷格翰国际有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2638040-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-27 | — | — | US | disclosed |
| US-6245769-B1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
| EP-1012151-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | Dupont Pharmaceuticals Company (US) | 2000-06-28 | — | — | EP | disclosed |
| CN-1230184-A | Arylamino fused pyridines and pyrimidines | DU PONT MERCK PHARMA (US) | 1999-09-29 | — | — | CN | disclosed |
| EP-0935601-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1999011643-A1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
| US-4720496-A | Pyridotriazoloquinazolines and triazolopyridoquinazolines useful as antiallergics | BOEHRINGER INGELHEIM KG (DE) | 1988-01-19 | — | — | US | disclosed |
| EP-0113911-A1 | Pyrido-triazoloquinazolines, their preparation and use | BOEHRINGER INGELHEIM KG (DE) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | SIRT2 2152/4885NOS1 4603/4885PRMT5 1567/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | SIRT2 4407/4885NOS1 4219/4885PRMT5 2908/4885 |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | CRH, CRHR1, CRHR2 | SIRT2 2966/4885NOS1 3854/4885PRMT5 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.